[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0016115A - Peptide derivatives of acrylamide, process for its preparation and use as tumor inhibiting agents - Google Patents

Peptide derivatives of acrylamide, process for its preparation and use as tumor inhibiting agents

Info

Publication number
BR0016115A
BR0016115A BR0016115-2A BR0016115A BR0016115A BR 0016115 A BR0016115 A BR 0016115A BR 0016115 A BR0016115 A BR 0016115A BR 0016115 A BR0016115 A BR 0016115A
Authority
BR
Brazil
Prior art keywords
hydrogen
different
preparation
inhibiting agents
peptide derivatives
Prior art date
Application number
BR0016115-2A
Other languages
Portuguese (pt)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0016115A publication Critical patent/BR0016115A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADOS PEPTìDICOS DE ACRILOìLA, PROCESSO PARA SUA PREPARAçãO E SEU USO COMO AGENTES INIBIDORES DE TUMOR". Compostos que são derivados peptídicos de acriloíla da fórmula (I) , onde n é 3 ou 4; m é 0, 1 ou 2; X e Y são iguais ou diferentes e são selecionados, independentemente para cada anel heterocíclico, de N ou CH; R~ 1~ e R~ 2~, iguais ou diferentes, são selecionados de hidrogênio, halogênio ou alquila C~ 1~-C~ 4~,; R~ 3~, é hidrogênio ou halogênio; B é selecionado dos grupos que consistem nas fórmulas (1) , (2) , (3) , (4) , (5), (6) e (7), onde R~ 4~/ R~ 5~, R~ 7~ e R~ 8~ são, independentemente entre si, hidrogênio ou alquila C~ 1~-C~ 4~; R~ 6~ é hidrogênio, hidróxi ou alquila C~ 1~-C~ 4~; ou um seu sal farmaceuticamente aceitável; desde que X e Y não sejam ambos átomos N para o mesmo anel-heterocíclico; quando todos de X e Y forem grupos CH e m for 0, então pelo menos um de R~ 4~, R~ 5~, ou R~ 6~ é diferente de hidrogênio; quando pelo menos um de X e Y for diferente de CH, então pelo menos um de R~ 4~ e R~ 5~, é diferente de hidrogênio; são úteis como agentes inibidores de tumor."PEPTIDIC DERIVATIVES FROM ACRYLOL, PROCESS FOR THEIR PREPARATION AND USE AS TUMOR INHIBITORS". Compounds that are acryloyl peptide derivatives of formula (I), where n is 3 or 4; m is 0, 1 or 2; X and Y are the same or different and are selected, independently for each heterocyclic ring, from N or CH; R ~ 1 ~ and R ~ 2 ~, the same or different, are selected from hydrogen, halogen or C ~ 1 ~ -C ~ 4 ~ alkyl; R ~ 3 ~, is hydrogen or halogen; B is selected from the groups consisting of formulas (1), (2), (3), (4), (5), (6) and (7), where R ~ 4 ~ / R ~ 5 ~, R ~ 7 ~ and R ~ 8 ~ are, independently of each other, hydrogen or C ~ 1 ~ -C ~ 4 ~ alkyl; R ~ 6 ~ is hydrogen, hydroxy or C ~ 1 ~ -C ~ 4 ~ alkyl; or a pharmaceutically acceptable salt thereof; provided that X and Y are not both N atoms for the same heterocyclic ring; when all of X and Y are groups CH and m is 0, then at least one of R ~ 4 ~, R ~ 5 ~, or R ~ 6 ~ is different from hydrogen; when at least one of X and Y is different from CH, then at least one of R ~ 4 ~ and R ~ 5 ~ is different from hydrogen; are useful as tumor inhibiting agents.

BR0016115-2A 1999-12-03 2000-11-23 Peptide derivatives of acrylamide, process for its preparation and use as tumor inhibiting agents BR0016115A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928703.9A GB9928703D0 (en) 1999-12-03 1999-12-03 Acryloyl peptidic derivatives,process for their preparation and their use as antitumour agents
PCT/EP2000/011714 WO2001040181A1 (en) 1999-12-03 2000-11-23 Acryloyl peptidic derivatives, process for their preparation and their use as antitumor agents

Publications (1)

Publication Number Publication Date
BR0016115A true BR0016115A (en) 2002-08-20

Family

ID=10865724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016115-2A BR0016115A (en) 1999-12-03 2000-11-23 Peptide derivatives of acrylamide, process for its preparation and use as tumor inhibiting agents

Country Status (10)

Country Link
EP (1) EP1242374A1 (en)
JP (1) JP2003515586A (en)
KR (1) KR20020084069A (en)
AU (1) AU781657B2 (en)
BR (1) BR0016115A (en)
CA (1) CA2395094A1 (en)
GB (1) GB9928703D0 (en)
NZ (1) NZ519581A (en)
WO (1) WO2001040181A1 (en)
ZA (1) ZA200204722B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011059D0 (en) 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
GB0015447D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015446D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
GB0016447D0 (en) 2000-07-04 2000-08-23 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
US6576612B1 (en) * 2000-10-02 2003-06-10 Pharmacia Italia S.P.A. Antitumor therapy comprising distamycin derivatives
US6969592B2 (en) 2001-09-26 2005-11-29 Pharmacia Italia S.P.A. Method for predicting the sensitivity to chemotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416005D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Peptidic compounds analogous to distamycin a and process for their preparation
GB9610079D0 (en) * 1996-05-14 1996-07-17 Pharmacia Spa Distamycin deriratives process for preparing them and their use as antitumor and antiviral agents
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB9806689D0 (en) * 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Acryloyl derivatives analogous to distamycin,process for preparing them,and their use as antitumour and antiviral agents

Also Published As

Publication number Publication date
JP2003515586A (en) 2003-05-07
WO2001040181A1 (en) 2001-06-07
GB9928703D0 (en) 2000-02-02
EP1242374A1 (en) 2002-09-25
CA2395094A1 (en) 2001-06-07
NZ519581A (en) 2004-05-28
AU2837001A (en) 2001-06-12
KR20020084069A (en) 2002-11-04
ZA200204722B (en) 2004-02-03
AU781657B2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
TR199800720T2 (en) 2-quinolone derivatives that inhibit farnesyl transferase.
TR200101884T2 (en) 4-mercaptopyrolidine derivatives as farnesyl transferase inhibitors.
UY24555A1 (en) NEW COMPOUNDS
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
RU95108387A (en) Diketopiperazine, process for preparing thereof, pharmaceutical composition, use of diketopiperazine
YU11997A (en) Lactamic derivatives and pharmaceutical compositions thereof
TR199800759T2 (en) Protein Kinase C Inhibitor.
ATE158288T1 (en) ANTIATHEROSCLEROTIC AND ANTITHRBOTIC 1-BENZOPYRAN-4-ONE AND 2-AMINO-1,3-BENZOXAZINE-4-ONE DERIVATIVES
ES2188584T3 (en) AMINA HETEROCICLICAL DERIVATIVES.
BR0007589A (en) Cell proliferation inhibitors
BR9911013A (en) Pyrazole derivatives as inhibitors of p-38 map kinase
BR0014136A (en) Compound, use of it, methods for the preparation of a compound, and to inhibit aurora 2 kinase in a warm-blooded animal, and pharmaceutical composition
BRPI0413232B8 (en) compound having inhibitory activity against sodium-dependent carrier, pharmaceutical composition comprising the compound, use of the compound in the preparation of a medicine, and process for preparing the compound
BR0014133A (en) Use of a compound, compound, methods of preparing a compound, and to inhibit aurora 2 kinase in a warm-blooded animal, and, pharmaceutical composition
TR199900920T2 (en) Naphthiridin t�revleri.
PT1140993E (en) GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
TR199902606T2 (en) Farnesyl transferase inhibitor quinazolinones.
BR0014225A (en) Pyrazole derivatives
DK0657458T3 (en) Inhibitors of protein kinase-C
SE9904505D0 (en) Novel compounds
BR9916566A (en) Ras-farnesyltransferase esulfobutylether-7-ß-cyclodextrin or 2-hydroxypropyl-ß-cyclodextrin inhibitor complex and process
TR199800011T1 (en) Benzo$g] quinoline t�revleri
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
ES2134801T3 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE.
HUP0103203A2 (en) Azaadamantane derivatives and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.